Abstract
The key oxygen sensing molecules, Prolyl-hydroxylase domain 1-3 enzymes (PHD1-3), regulate hypoxia-inducible factor (HIF) under hypoxia. In the settings of cardiomyopathy and ischemia-reperfusion injury, PHD3 expression is elevated, resulting in decreased HIF activation. The role of PHD3 in myocardial injury is poorly understood. Hence, we aimed to determine the effects of PHD3 deletion in mice on HIF-1α and other related pathways following myocardial infarction (MI). Left coronary artery (LAD) in both wild type and prolyl hydroxylase 3 knock out (PHD3-/-) mice was ligated to induce myocardial infarction. Electrophoretic mobility shift analysis showed significant increase in DNA-binding activity of HIF-1α in PHD3-/- mice as compared to wild type (WT) mice post MI. The PHD3-/-MI group also showed decreased fibrosis. Seven days after MI, enhanced capillary / arteriolar density was observed compared to WTMI group. PHD3-/- mice subjected to MI also showed improved cardiac functions (Ejection fraction and Fractional shortening), as assessed by echocardiogram, compared to WT. Western blot analysis showed increased VEGF, Ang-1 & Bcl-2 expression in PHD3-/-MI group. In conclusion, ablation of the PHD3 gene resulted in increased angiogenesis and cardiac function after infarction thereby offering a potential target for pharmacological management of ischemic myocardial disease.
Keywords: Angiogenesis, myocardial infarction, Bcl-2, VEGF, HIF, prolyl hydroxylase.
Current Pharmaceutical Design
Title:Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Volume: 20 Issue: 9
Author(s): Babatunde Oriowo, Mahesh Thirunavukkarasu, Vaithinathan Selvaraju, Ram Sudheer Adluri, Lijun Zhan, Kotaro Takeda, Guo-Hua Fong, Juan A. Sanchez and Nilanjana Maulik
Affiliation:
Keywords: Angiogenesis, myocardial infarction, Bcl-2, VEGF, HIF, prolyl hydroxylase.
Abstract: The key oxygen sensing molecules, Prolyl-hydroxylase domain 1-3 enzymes (PHD1-3), regulate hypoxia-inducible factor (HIF) under hypoxia. In the settings of cardiomyopathy and ischemia-reperfusion injury, PHD3 expression is elevated, resulting in decreased HIF activation. The role of PHD3 in myocardial injury is poorly understood. Hence, we aimed to determine the effects of PHD3 deletion in mice on HIF-1α and other related pathways following myocardial infarction (MI). Left coronary artery (LAD) in both wild type and prolyl hydroxylase 3 knock out (PHD3-/-) mice was ligated to induce myocardial infarction. Electrophoretic mobility shift analysis showed significant increase in DNA-binding activity of HIF-1α in PHD3-/- mice as compared to wild type (WT) mice post MI. The PHD3-/-MI group also showed decreased fibrosis. Seven days after MI, enhanced capillary / arteriolar density was observed compared to WTMI group. PHD3-/- mice subjected to MI also showed improved cardiac functions (Ejection fraction and Fractional shortening), as assessed by echocardiogram, compared to WT. Western blot analysis showed increased VEGF, Ang-1 & Bcl-2 expression in PHD3-/-MI group. In conclusion, ablation of the PHD3 gene resulted in increased angiogenesis and cardiac function after infarction thereby offering a potential target for pharmacological management of ischemic myocardial disease.
Export Options
About this article
Cite this article as:
Oriowo Babatunde, Thirunavukkarasu Mahesh, Selvaraju Vaithinathan, Adluri Sudheer Ram, Zhan Lijun, Takeda Kotaro, Fong Guo-Hua, Sanchez A. Juan and Maulik Nilanjana, Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction, Current Pharmaceutical Design 2014; 20 (9) . https://dx.doi.org/10.2174/13816128113199990549
DOI https://dx.doi.org/10.2174/13816128113199990549 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry Sirtuins: Novel Players in Male Reproductive Health
Current Medicinal Chemistry Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews PREFACE: Cardiovascular and Hematological Medicine in 2015 - Advances and Insights
Cardiovascular & Hematological Agents in Medicinal Chemistry Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Galanthus nivalis Agglutinin (GNA)-Related Lectins: Traditional Proteins, Burgeoning Drugs?
Current Chemical Biology Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Nearly 200 X-Ray Crystal Structures of Transthyretin: What Do They Tell Us About This Protein and the Design of Drugs for TTR Amyloidoses?
Current Medicinal Chemistry New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design